---
id: typhoid-fever_060
category: organisms
tags: [typhoid-fever, salmonella-typhi, enteric-fever, rose-spots, XDR-typhoid, azithromycin, ceftriaxone]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Typhoid Fever (Salmonella typhi)

**Q:** What are the clinical features, complications, and current treatment (including XDR strains) of typhoid fever?

**A:**

**Microbiology:**
- **Salmonella enterica serovar Typhi** (S. typhi)
- Gram-negative rod (Enterobacterales)
- Human-restricted pathogen (no animal reservoir)
- Related: **Salmonella paratyphi** (causes paratyphoid fever - milder)

**Epidemiology:**
- **11-21 million cases/year worldwide** (~200,000 deaths)
- Endemic: South Asia (India, Pakistan, Bangladesh), sub-Saharan Africa
- US: ~350 cases/year (80% travel-related)
- Transmission: Fecal-oral (contaminated food/water), chronic carriers

---

**Clinical Presentation:**

**Incubation:** 6-30 days (average 10-14 days)

**Typical Course (Without Treatment):**

**Week 1: Rising Fever**
- **Stepwise fever** (increases daily, "staircase" pattern)
- **Headache** (severe, frontal)
- **Myalgias**
- **Malaise, anorexia**
- **Constipation** (more common than diarrhea initially!)
- **Dry cough** (non-productive)

**Week 2: Sustained Fever + Abdominal Symptoms**
- **Sustained high fever** (39-40°C, "continuous fever")
- **Rose spots** (30%): 2-4 mm blanching pink macules on trunk/abdomen
- **Hepatosplenomegaly** (60%)
- **Relative bradycardia** (pulse-temperature dissociation)
- **Abdominal pain, distention**
- **"Pea soup" diarrhea** or constipation

**Week 3: Complications (If Untreated)**
- **Intestinal perforation** (1-3%) → peritonitis
- **Intestinal hemorrhage** (10%)
- **Encephalopathy** ("typhoid state": delirium, obtundation)
- **Myocarditis**

**Week 4: Recovery (Or Death)**
- Defervescence if surviving
- Mortality ~10-30% if untreated
- **3-5% become chronic carriers** (fecal shedding >1 year)

**Key Features:**
- **Fever in a returning traveler** (South Asia)
- **Sustained fever + relative bradycardia + rose spots** = classic triad

---

**Diagnosis:**

**Blood Culture (Gold Standard):**
- **Positive in 60-80% during first week**
- Decreases after antibiotic exposure
- **Best diagnostic test early in illness**

**Stool Culture:**
- Positive in 30-40% (week 2-3)
- Less sensitive than blood culture early

**Bone Marrow Culture:**
- **Most sensitive (90%)** but rarely done
- Positive even after antibiotics

**Serology (Widal Test):**
- **Not recommended** (low sensitivity/specificity)

**PCR:**
- Emerging, not widely available

---

**Complications:**

**Gastrointestinal:**
- **Intestinal perforation** (usually terminal ileum) - 1-3%
- **GI hemorrhage** - 10%

**Neurologic:**
- **Encephalopathy** ("typhoid state")
- Meningitis (rare)

**Cardiovascular:**
- Myocarditis
- **Mycotic aneurysms** (rare but serious)

**Hematologic:**
- DIC
- Hemolytic anemia

**Chronic Carriage:**
- **3-5% of patients** become chronic carriers
- Defined as shedding S. typhi in stool >1 year post-infection
- Reservoir in **gallbladder** (chronic cholecystitis)
- Treatment: Prolonged antibiotics ± cholecystectomy

---

**Treatment:**

**Historical Treatment (No Longer First-Line):**
- Chloramphenicol, ampicillin, TMP-SMX → widespread resistance

**Current Treatment (2024 WHO Recommendations):**

**1. Uncomplicated Typhoid (Fully Susceptible Strains):**

| **Antibiotic** | **Dosing** | **Duration** |
|----------------|------------|--------------|
| **Azithromycin** (preferred) | 1g PO daily (or 500 mg daily) | 5-7 days |
| **Ciprofloxacin** | 500 mg PO BID | 5-7 days |
| **Ceftriaxone** | 2g IV daily | 7-14 days |

**2. Fluoroquinolone-Resistant (South Asia - Common):**

- **Azithromycin** 1g PO daily x 5-7 days (preferred)
- **Ceftriaxone** 2g IV daily x 7-14 days

**3. Extensively Drug-Resistant (XDR) Typhoid:**

**Definition:**
- Resistant to chloramphenicol, ampicillin, TMP-SMX, fluoroquinolones, **AND ceftriaxone**
- Emerged in **Pakistan** (2016), now spreading

**XDR Strains Susceptible to:**
- Azithromycin (for now)
- Carbapenems (meropenem)
- Tigecycline

**XDR Treatment:**

| **Severity** | **Regimen** | **Duration** |
|--------------|-------------|--------------|
| **Uncomplicated (from Pakistan)** | **Azithromycin** 1g PO daily | 7 days |
| **Severe/complicated (from Pakistan)** | **Meropenem** 1g IV q8h → switch to azithromycin PO | ≥7 days total |

**Key Point:**
- **Pakistan travel + suspected typhoid** → assume XDR, use azithromycin

**4. Severe/Complicated Typhoid:**

- **Ceftriaxone** 2g IV q12-24h (if susceptible)
- **Meropenem** (if XDR or ceftriaxone-resistant)
- **Dexamethasone** 3 mg/kg IV x1, then 1 mg/kg q6h x 8 doses (if shock or severe encephalopathy)

---

**Resistance Patterns (2024):**

**Global Resistance Trends:**
- **Fluoroquinolone resistance:** >90% in South Asia
- **Ceftriaxone resistance:** Emerging (XDR strains)
- **Azithromycin resistance:** Emerging in South/Southeast Asia (Bangladesh, Cambodia, India, Nepal, Pakistan)

**XDR Typhoid (Pakistan Strain - REPJPP01):**
- Resistant to: Chloramphenicol, ampicillin, TMP-SMX, fluoroquinolones, ceftriaxone
- **89% of US cases from Pakistan are XDR**
- Only azithromycin, carbapenems, tigecycline effective

**Concern:**
- **Azithromycin resistance emerging** → if widespread, XDR typhoid will require carbapenems

---

**Chronic Carrier Treatment:**

**Definition:** Stool positive for S. typhi >1 year

**Treatment:**

| **Regimen** | **Dosing** | **Duration** |
|-------------|------------|--------------|
| **Ciprofloxacin** (if susceptible) | 500 mg PO BID | **28 days** |
| **Azithromycin** | 1g PO weekly | **6 weeks** |
| **Cholecystectomy** | If gallstones or antibiotic failure | — |

**Note:** Chronic carriers with gallstones often require cholecystectomy for cure

---

**Prevention:**

**Vaccination:**

**Two Vaccines Available:**

| **Vaccine** | **Type** | **Dosing** | **Efficacy** | **Duration** |
|-------------|----------|------------|--------------|--------------|
| **Ty21a (Vivotif)** | Live attenuated oral | 1 capsule every other day x 4 doses | 50-80% | 5 years |
| **Vi polysaccharide (Typhim Vi)** | Injectable | 0.5 mL IM x1 | 50-80% | 2-3 years |

**Indications:**
- Travelers to endemic areas (South Asia, sub-Saharan Africa)
- Lab workers handling S. typhi
- Close contacts of chronic carriers

**Limitations:**
- **Do NOT provide 100% protection** (still need food/water precautions)
- Do NOT protect against paratyphoid fever

**Food/Water Precautions:**
- "Boil it, cook it, peel it, or forget it"

---

**Comparison: Typhoid vs Nontyphoidal Salmonella**

| **Feature** | **Typhoid (S. typhi)** | **Nontyphoidal Salmonella** |
|-------------|------------------------|------------------------------|
| **Syndrome** | Systemic febrile illness | Gastroenteritis |
| **Bacteremia** | ✅ 100% | 5-10% |
| **Diarrhea** | Variable (constipation early) | ✅ Prominent |
| **Rose spots** | ✅ 30% | ❌ No |
| **Hepatosplenomegaly** | ✅ 60% | ❌ Rare |
| **Antibiotics** | **Always required** | Usually NOT needed |
| **Mortality (untreated)** | 10-30% | <1% |
| **Chronic carrier** | 3-5% | Rare |

---

**Mnemonic: "TYPHOID = Typhi Has Yucky Pakistan Hazards, Oral Infection, Death"**
- **T**raveler from South Asia
- **Y**ellow rose spots (actually pink)
- **P**akistan = XDR strains
- **H**epatosplenomegaly
- **O**ral transmission (fecal-oral)
- **I**ntestinal perforation (complication)
- **D**eath if untreated (10-30%)

**Mnemonic: "XDR = eXtremely Dangerous Resistance (Pakistan)"**
- **X**DR = resistant to all first-line agents + ceftriaxone
- **D**angerous (mortality ↑ if mismanaged)
- **R**equires azithromycin or carbapenems

**Clinical Pearls:**
- **Typhoid fever = systemic illness, NOT just diarrhea** (constipation more common early!)
- **Sustained fever + rose spots + hepatosplenomegaly** = classic triad
- **Relative bradycardia** (pulse-temp dissociation) is a clue
- **Pakistan travel** → assume XDR, use azithromycin empirically
- **Blood culture (week 1) > stool culture** for diagnosis
- **Do NOT use fluoroquinolones empirically** in South Asia travelers (>90% resistance)
- XDR typhoid requires azithromycin (uncomplicated) or meropenem (severe)
- **Azithromycin resistance emerging** → future may require carbapenems for all XDR
- Chronic carriers harbor S. typhi in gallbladder → may require cholecystectomy
- Typhoid vaccines only 50-80% effective → still need food/water precautions

**Media:** None

**Sources:** [CDC Yellow Book 2024 - Typhoid & paratyphoid fever], [WHO 2024 - Typhoid treatment], [CDC MMWR 2019 - XDR Salmonella typhi], [CDC 2024 - Emerging XDR strain data], [PMC 2024 - Azithromycin-resistant S. typhi Southeast Asia], [PMC 2022 - Treatment with cephalosporins], [Medscape 2024 - Typhoid medication], [MSF Medical Guidelines - Enteric fevers]
